SE504184C2 - Användning av vissa 3-HT3-antagonister för framställning av läkemedel - Google Patents

Användning av vissa 3-HT3-antagonister för framställning av läkemedel

Info

Publication number
SE504184C2
SE504184C2 SE8702980A SE8702980A SE504184C2 SE 504184 C2 SE504184 C2 SE 504184C2 SE 8702980 A SE8702980 A SE 8702980A SE 8702980 A SE8702980 A SE 8702980A SE 504184 C2 SE504184 C2 SE 504184C2
Authority
SE
Sweden
Prior art keywords
formula
alkyl
group
compound
hydrogen
Prior art date
Application number
SE8702980A
Other languages
English (en)
Swedish (sv)
Other versions
SE8702980D0 (sv
SE8702980L (sv
Inventor
Moise Azria
Karl-Heinz Buchheit
Keith Arnold Dixon
Guenther Engel
Rudolf K A Giger
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB868618614A external-priority patent/GB8618614D0/en
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of SE8702980D0 publication Critical patent/SE8702980D0/xx
Publication of SE8702980L publication Critical patent/SE8702980L/xx
Publication of SE504184C2 publication Critical patent/SE504184C2/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C07D451/12—Oxygen atoms acylated by aromatic or heteroaromatic carboxylic acids, e.g. cocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
SE8702980A 1986-07-30 1987-07-28 Användning av vissa 3-HT3-antagonister för framställning av läkemedel SE504184C2 (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB868618614A GB8618614D0 (en) 1986-07-30 1986-07-30 Treatment of psychiatric disorders
DE3626703 1986-08-07

Publications (3)

Publication Number Publication Date
SE8702980D0 SE8702980D0 (sv) 1987-07-28
SE8702980L SE8702980L (sv) 1988-04-28
SE504184C2 true SE504184C2 (sv) 1996-12-02

Family

ID=25846334

Family Applications (2)

Application Number Title Priority Date Filing Date
SE8702980A SE504184C2 (sv) 1986-07-30 1987-07-28 Användning av vissa 3-HT3-antagonister för framställning av läkemedel
SE19939300978A SE9300978D0 (sv) 1986-07-30 1993-03-24 Terapeutisk anvaendning av serotoninantagonister

Family Applications After (1)

Application Number Title Priority Date Filing Date
SE19939300978A SE9300978D0 (sv) 1986-07-30 1993-03-24 Terapeutisk anvaendning av serotoninantagonister

Country Status (26)

Country Link
US (1) US5561149A (hu)
JP (1) JP2632858B2 (hu)
KR (1) KR950014445B1 (hu)
AU (2) AU642210B2 (hu)
BE (1) BE1005921A4 (hu)
CA (1) CA1327750C (hu)
CH (1) CH675072A5 (hu)
CY (2) CY1754A (hu)
DE (1) DE3724059A1 (hu)
DK (1) DK392487A (hu)
ES (2) ES2010227A6 (hu)
FI (1) FI873280A (hu)
FR (1) FR2602142B1 (hu)
GB (3) GB2193633B (hu)
GR (1) GR871212B (hu)
HK (3) HK2694A (hu)
HU (2) HU202108B (hu)
IE (1) IE61103B1 (hu)
IL (2) IL83363A (hu)
IT (1) IT1218150B (hu)
LU (1) LU86950A1 (hu)
MY (1) MY101863A (hu)
NL (1) NL8701682A (hu)
NO (1) NO873133L (hu)
NZ (1) NZ221226A (hu)
SE (2) SE504184C2 (hu)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3688296T2 (de) * 1985-03-14 1993-11-04 Beecham Group Plc Arzneimittel zur behandlung von erbrechen.
GB8518658D0 (en) * 1985-07-24 1985-08-29 Glaxo Group Ltd Medicaments
JP2765845B2 (ja) * 1986-11-21 1998-06-18 グラクソ、グループ、リミテッド 中止症候群の予防の治療薬
GB8627909D0 (en) * 1986-11-21 1986-12-31 Glaxo Group Ltd Medicaments
US5198447A (en) * 1986-11-21 1993-03-30 Glaxo Group Limited Medicaments
EP0559297B1 (en) * 1986-12-17 1997-05-07 Glaxo Group Limited Use of heterocyclic derivatives for the manufacture of medicaments
US4973594A (en) * 1986-12-17 1990-11-27 Glaxo Group Limited Medicaments
US5244909A (en) * 1986-12-17 1993-09-14 Glaxo Group Limited Methods for the treatment of cognitive disorders
PH25025A (en) * 1986-12-17 1991-01-28 Glaxo Group Ltd A method of treating dementia and other cognitive disorders using 1,2,3,9-tetrahydro-9-methyl-3-((2-methyl-1h-imidazol-1-yl)methyl)-4h-carbazol-4-one
US5246941A (en) 1986-12-17 1993-09-21 Glaxo Group Limited Method for the treatment of depression
GB8630071D0 (en) * 1986-12-17 1987-01-28 Glaxo Group Ltd Medicaments
US5200414A (en) * 1986-12-17 1993-04-06 Glaxo Group Limited Methods for the treatment of cognitive disorders
US5190954A (en) * 1986-12-17 1993-03-02 Glaxo Group Limited Methods for the treatment of cognitive disorders
NZ227841A (en) * 1988-02-12 1991-08-27 Merck Sharp & Dohme Heterocyclic compounds with at least two non-condensed five membered rings and pharmaceutical compositions
GB8808433D0 (en) * 1988-04-11 1988-05-11 Merck Sharp & Dohme Therapeutic agents
IT1226389B (it) * 1988-07-12 1991-01-15 Angeli Inst Spa Nuovi derivati ammidinici e guanidinici
US5229407A (en) * 1988-09-01 1993-07-20 Glaxo Group Limited Medicaments
US5221687A (en) * 1988-09-01 1993-06-22 Glaxo Group Limited Medicaments
GB8904551D0 (en) * 1989-02-28 1989-04-12 Glaxo Group Ltd Chemical compounds
DE69004924T2 (de) 1989-04-21 1994-05-19 Sandoz Ag Therapeutische verwendung von 5-ht3-rezeptor-antagonisten.
US5530008A (en) * 1989-04-21 1996-06-25 Sandoz Ltd. Use of 5-HT3 receptor antagonists in treating panic disorders or obsessive compulsive disorders
CA2017621A1 (en) * 1989-06-23 1990-12-23 Masayuki Kato Indole derivatives and processes for preparation thereof
GB8917557D0 (en) * 1989-08-01 1989-09-13 Glaxo Group Ltd Medicaments
GB8917556D0 (en) * 1989-08-01 1989-09-13 Glaxo Group Ltd Medicaments
CA2030051C (en) * 1989-11-17 2001-08-07 Haruhiko Kikuchi Indole derivatives
US5225407A (en) * 1990-02-22 1993-07-06 Glaxo Group Limited 5-HT3 receptor antagonists for the treatment of autism
US5187166A (en) * 1990-07-31 1993-02-16 Nisshin Flour Milling Co., Ltd. Azabicyclo derivatives and their use as antiemetics
GB9020927D0 (en) * 1990-09-26 1990-11-07 Beecham Group Plc Pharmaceuticals
HU211081B (en) * 1990-12-18 1995-10-30 Sandoz Ag Process for producing indole derivatives as serotonin antagonists and pharmaceutical compositions containing the same
EP0492020A1 (en) * 1990-12-21 1992-07-01 Merrell Dow Pharmaceuticals Inc. Use of certain esters of hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3(4H)-one and related compounds for treating cognitive disorders
ES2080482T3 (es) * 1990-12-28 1996-02-01 Kyowa Hakko Kogyo Kk Derivado de quinoleina.
JP3026845B2 (ja) * 1991-02-20 2000-03-27 日清製粉株式会社 ピペリジン誘導体
DE4115215A1 (de) * 1991-05-10 1992-11-12 Merck Patent Gmbh Indolderivate
US5955470A (en) * 1991-06-11 1999-09-21 Merrell Pharmaceuticals, Inc. Derivatives of amide analogs of certain methano bridged quinolizines
EP0591434A4 (en) * 1991-06-26 1994-09-14 Sepracor Inc Method and compositions for treating emesis, nausea and other disorders using optically pure r(+) ondansetron
GB9121170D0 (en) * 1991-10-05 1991-11-20 Smithkline Beecham Plc Pharmaceuticals
US5344831A (en) * 1992-01-31 1994-09-06 Nisshin Flour Milling Co., Ltd. Diazabicyclo derivatives
US5474994A (en) * 1992-05-26 1995-12-12 Recordati S.A., Chemical And Pharmaceutical Company Bicyclic heterocyclic derivatives having α1 -adrenergic and 5HT1A
US5605896A (en) * 1992-02-25 1997-02-25 Recordati S.A., Chemical And Pharmaceutical Company Bicyclic heterocyclic derivatives having α1 adrenergic and 5HT1A activities
IT1254469B (it) * 1992-02-25 1995-09-25 Recordati Chem Pharm Derivati benzopiranici e benzotiopiranici
JPH05310732A (ja) * 1992-03-12 1993-11-22 Mitsubishi Kasei Corp シンノリン−３−カルボン酸誘導体
JP2699794B2 (ja) * 1992-03-12 1998-01-19 三菱化学株式会社 チエノ〔３，２−ｂ〕ピリジン誘導体
IT1258315B (it) * 1992-04-10 1996-02-22 Recordati Chem Pharm Derivati del flavone
US5840903A (en) 1992-07-27 1998-11-24 G. D. Searle & Co. 4-aminomethyl-1-azaadamantane derived benzamides
ES2062921B1 (es) * 1992-11-06 1995-06-16 Merck Patent Gmbh 3-(indol-2-carboxiamido)quinuclidinas.
US5330986A (en) * 1992-11-24 1994-07-19 Hoechst-Roussel Pharmaceuticals Inc. Indole-7-carboxamide derivatives
US5354757A (en) * 1992-12-15 1994-10-11 G. D. Searle & Co. Azanoradamantanes
US5530018A (en) * 1994-02-04 1996-06-25 G. D. Searle & Co. Meso-azanoradamantanes
US5399562A (en) * 1994-02-04 1995-03-21 G. D. Searle & Co. Indolones useful as serotonergic agents
FR2747386B1 (fr) * 1996-04-12 1998-05-15 Synthelabo Derives de 3-[(1,2,3,4-tetrahydroisoquinolein-2-yl)methyl] -8-azabicyclo [3.2.1] octane, leur preparation et leur application en therapeutique
US6150420A (en) * 1998-06-01 2000-11-21 Theramax, Inc. Method for enhanced brain delivery of bupropion
WO2000003701A1 (en) * 1998-07-16 2000-01-27 Massachusetts Institute Of Technology Composition for treatment of stress
US6579899B1 (en) 1998-07-16 2003-06-17 Massachusetts Institute Of Technology Composition for treatment of stress
WO2000051582A2 (en) 1999-03-01 2000-09-08 Sepracor Inc. Methods for treating apnea and apnea disorders using optically pure r(+)ondansetron
US6486172B2 (en) 2000-08-18 2002-11-26 Pharmacia & Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
US6492385B2 (en) 2000-08-18 2002-12-10 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
US6479510B2 (en) 2000-08-18 2002-11-12 Pharmacia & Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
AU2001282875A1 (en) 2000-08-21 2002-03-04 Pharmacia And Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
WO2002015662A2 (en) 2000-08-21 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists
PE20021019A1 (es) 2001-04-19 2002-11-13 Upjohn Co Grupos azabiciclicos sustituidos
US20030044356A1 (en) * 2001-04-20 2003-03-06 Jin Auh Composition for nasal solution sprays having effective component of 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one)
AR036041A1 (es) * 2001-06-12 2004-08-04 Upjohn Co Compuestos aromaticos heterociclicos sustituidos con quinuclidina y composiciones farmaceuticas que los contienen
AR036040A1 (es) 2001-06-12 2004-08-04 Upjohn Co Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen
EP1419162A1 (en) * 2001-08-24 2004-05-19 Pharmacia &amp; Upjohn Company Substituted-aryl 7-aza 2.2.1]bicycloheptanes for the treatment of disease
BR0212101A (pt) 2001-08-24 2004-08-24 Pharmacia & Up John Company 7-aza [2.2.1] biciclo-heptanos substituìdos com heteroarila para o tratamento de doenças
DE60218493D1 (de) * 2001-09-12 2007-04-12 Pharmacia & Upjohn Co Llc Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten
KR100614900B1 (ko) 2001-10-02 2006-08-25 파마시아 앤드 업존 캄파니 엘엘씨 질병의 치료를 위한 아자비시클릭-치환된 융합-헤테로아릴화합물
BR0213760A (pt) * 2001-10-26 2004-10-19 Upjohn Co Composto, composição farmacêutica, uso do composto e método para tratamento de doença ou condição
US6849620B2 (en) 2001-10-26 2005-02-01 Pfizer Inc N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease
WO2003040147A1 (en) * 2001-11-08 2003-05-15 Pharmacia & Upjohn Company Azabicyclic-substituted-heteroaryl compounds for the treatment of disease__________________________________________________________________________________________________________________________
EP1442037A1 (en) 2001-11-09 2004-08-04 PHARMACIA &amp; UPJOHN COMPANY Azabicyclic-phenyl-fused-heterocyclic compounds and their use as alpha7 nachr ligands
DE10156719A1 (de) 2001-11-19 2003-05-28 Bayer Ag Heteroarylcarbonsäureamide
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
MXPA04007936A (es) 2002-02-15 2004-11-26 Upjohn Co Compuestos de aril-sustituidos para el tratamiento de enfermedades.
EP1476448A2 (en) * 2002-02-19 2004-11-17 PHARMACIA &amp; UPJOHN COMPANY Azabicyclic compounds for the treatment of disease
AU2003219690A1 (en) * 2002-02-19 2003-09-09 Pharmacia And Upjohn Company Fused bicyclic-n-bridged-heteroaromatic carboxamides for the treatment of disease
JP2005525357A (ja) * 2002-02-20 2005-08-25 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー α７ニコチン性アセチルコリン受容体活性を伴うアザ二環式化合物
GB0217920D0 (en) * 2002-04-23 2002-09-11 Aventis Pharm Prod Inc Interleukin-4 Gene Expression inhibitors
DE10234424A1 (de) 2002-07-29 2004-02-12 Bayer Ag Benzothiophen-, Benzofuran- und Indolharnstoffe
JP2005537297A (ja) * 2002-08-01 2005-12-08 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー アルファ−７ｎａｃｈｒ活性を有する１ｈ−ピラゾールおよび１ｈ−ピロール−アザビシクロ化合物
DE10241407A1 (de) * 2002-09-06 2004-03-18 Elbion Ag Behandlung nicht allergischer Rhinitis durch selektive Phosphodiesterase 4-Hemmstoffe
EE05516B1 (et) * 2002-09-25 2012-02-15 Memory@Pharmaceuticals@Corporation Indasoolid bensotiasoolid ja bensoisotiasoolid nende valmistamine ning kasutamine
EP1562959A2 (en) * 2002-11-01 2005-08-17 Pharmacia & Upjohn Company LLC Compounds having both alpha7 nachr agonist and 5ht antagonist activity for treatment of cns diseases
ES2295973T3 (es) * 2003-12-22 2008-04-16 Memory Pharmaceuticals Corporation Indoles, 1h-indazoles, 1,2-bencisoxazoles, y 1,2-bencisotiazoles, y preparacion y usos de los mismos.
TW200533348A (en) * 2004-02-18 2005-10-16 Theravance Inc Indazole-carboxamide compounds as 5-ht4 receptor agonists
EP1735306A2 (en) 2004-03-25 2006-12-27 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof
US7728006B2 (en) * 2004-04-07 2010-06-01 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
TWI351282B (en) * 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
US8309575B2 (en) 2004-04-07 2012-11-13 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
DE602005024677D1 (de) * 2004-04-22 2010-12-23 Memory Pharm Corp Indole, 1h-indazole, 1,2-benzisoxazole, 1,2-benzoisothiazole, deren herstellung und verwendungen
BRPI0510212A (pt) * 2004-05-07 2007-10-16 Memory Pharm Corp 1h-indazóis, benzotiazóis, 1,2 - benzoisoxazóis, 1,2-benzoisotiazóis, e cromonas e a preparação e usos dos mesmos
ES2332808T3 (es) * 2004-11-05 2010-02-12 Theravance, Inc. Compuestos agonistas del receptor 5-ht4.
JP5042028B2 (ja) * 2004-11-05 2012-10-03 セラヴァンス， インコーポレーテッド キノリノン−カルボキサミド化合物
RU2418797C2 (ru) 2004-12-22 2011-05-20 Мемори Фармасьютиклз Корпорейшн Лиганды никотинового рецептора альфа-7, их получение и применение
US7419989B2 (en) * 2004-12-22 2008-09-02 Theravance, Inc. Indazole-carboxamide compounds
BRPI0608392A2 (pt) * 2005-03-02 2009-12-29 Theravance Inc compostos de quinolinona como agonistas do receptor 5-ht4
ES2264901B1 (es) * 2005-07-06 2007-12-01 Inke, S.A. Procedimiento para la obtencion de un compuesto farmaceuticamente activo, sus intermedios de sintesis y procedimiento para la obtencion de los mismos.
DE602006003227D1 (de) * 2005-07-06 2008-11-27 Inke Sa Verfahren zur gewinnung der pharmazeutisch aktivendavon und verfahren zu deren gewinnung
US8106066B2 (en) * 2005-09-23 2012-01-31 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof
MX2009010174A (es) * 2007-03-23 2009-10-12 Abbott Lab Derivados de aza-adamantano ester y carbamato y metodos de uso de los mismos.
CN101883771A (zh) * 2007-10-01 2010-11-10 科门蒂斯公司 作为α7-烟碱乙酰胆碱受体配体用于治疗阿尔茨海默氏病的奎宁环-4-基甲基1H-吲哚-3-甲酸酯衍生物
ES2396300T3 (es) 2008-11-19 2013-02-20 Envivo Pharmaceuticals, Inc. Tratamiento de trastornos cognitivos con (R)-7-cloro-N-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma
CN102802620A (zh) * 2009-05-11 2012-11-28 英维沃医药有限公司 使用某种α-7烟酸受体与乙酰胆碱酯酶抑制剂结合治疗认知障碍
US20100298397A1 (en) * 2009-05-19 2010-11-25 Singh Nikhilesh N Method of treatment of obsessive compulsive disorder with ondansetron
WO2011094545A2 (en) 2010-01-28 2011-08-04 President And Fellows Of Harvard College Compositions and methods for enhancing proteasome activity
WO2011146511A1 (en) 2010-05-17 2011-11-24 Envivo Pharmaceuticals, Inc. A crystalline form of (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate
CN103635230B (zh) 2011-05-12 2017-10-31 普罗蒂斯特斯治疗公司 蛋白内稳态调节剂
AU2013259871A1 (en) 2012-05-08 2014-11-20 Forum Pharmaceuticals Inc. Methods of maintaining, treating or improving cognitive function
US9849135B2 (en) 2013-01-25 2017-12-26 President And Fellows Of Harvard College USP14 inhibitors for treating or preventing viral infections
US9050325B2 (en) * 2013-04-08 2015-06-09 Abdul Zahir Ondansetron nasal spray composition
WO2015073528A1 (en) 2013-11-12 2015-05-21 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
US9434724B2 (en) 2014-07-11 2016-09-06 Alpharmagen, Llc Quinuclidines for modulating alpha 7 activity

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB214772A (en) * 1923-02-17 1924-05-01 James Walter Henry Dew Improved clothes-dryer applicable for other purposes
IL59004A0 (en) * 1978-12-30 1980-03-31 Beecham Group Ltd Substituted benzamides their preparation and pharmaceutical compositions containing them
FR2493848B2 (fr) * 1980-11-07 1986-05-16 Delalande Sa Nouveaux derives des nor-tropane et granatane, leur procede de preparation et leur application en therapeutique
FR2531083B1 (fr) * 1982-06-29 1986-11-28 Sandoz Sa Nouveaux derives de la piperidine, leur preparation et leur utilisation comme medicaments
FR2529548A1 (fr) * 1982-07-02 1984-01-06 Delalande Sa Nouveaux derives de l'amino-3 quinuclidine, leur procede et leur application en therapeutique
EP0099194A3 (en) * 1982-07-03 1984-04-11 Beecham Group Plc Novel benzamides
JPS5936675A (ja) * 1982-07-13 1984-02-28 サンド・アクチエンゲゼルシヤフト 二環性複素環式カルボン酸アザビシクロアルキルエステルまたはアミド
CH664567A5 (de) * 1983-08-26 1988-03-15 Sandoz Ag Aromatische carbonsaeure- und sulfonsaeureester oder -amide.
FR2557110B1 (fr) * 1983-12-23 1989-11-24 Sandoz Sa Nouveaux derives d'amines cycliques, leur preparation et leur utilisation comme medicaments
FI84349C (fi) * 1984-01-25 1991-11-25 Glaxo Group Ltd Foerfarande foer framstaellning av en farmakologiskt vaerdefull foerening.
DE3680123D1 (en) * 1985-01-23 1991-08-14 Glaxo Group Ltd Tetrahydrocarbazolonderivate.
DE3688296T2 (de) * 1985-03-14 1993-11-04 Beecham Group Plc Arzneimittel zur behandlung von erbrechen.
GB8525913D0 (en) * 1985-10-21 1985-11-27 Beecham Group Plc Compounds
DE3650772T2 (de) * 1985-04-27 2003-04-03 F. Hoffmann-La Roche Ag, Basel Derivate von Indazole-3-carboxamide und -3-carboxylsäure
GB8518658D0 (en) * 1985-07-24 1985-08-29 Glaxo Group Ltd Medicaments
GB8520616D0 (en) * 1985-08-16 1985-09-25 Beecham Group Plc Compounds
ES2053451T3 (es) * 1986-01-07 1994-08-01 Beecham Group Plc Un procedimiento para la preparacion de un compuesto que tiene propiedades farmacologicas utiles.
EP0235878A3 (en) * 1986-01-16 1989-06-14 Beecham Group Plc Novel compounds

Also Published As

Publication number Publication date
US5561149A (en) 1996-10-01
NL8701682A (nl) 1988-02-16
FI873280A0 (fi) 1987-07-28
GB2193633B (en) 1991-04-17
CA1327750C (en) 1994-03-15
KR950014445B1 (ko) 1995-11-28
NO873133D0 (no) 1987-07-27
GB2231265B (en) 1991-04-24
IL83363A (en) 1993-07-08
AU642210B2 (en) 1993-10-14
HUT45895A (en) 1988-09-28
CH675072A5 (hu) 1990-08-31
GB2231264B (en) 1991-04-24
MY101863A (en) 1992-01-31
SE9300978A0 (sv) 1993-03-24
CY1753A (en) 1994-06-03
JPS6341429A (ja) 1988-02-22
IE872051L (en) 1988-01-30
GR871212B (en) 1987-12-15
FR2602142B1 (fr) 1996-07-05
GB8717768D0 (en) 1987-09-03
IT8748211A0 (it) 1987-07-23
FI873280A (fi) 1988-01-31
SE9300978D0 (sv) 1993-03-24
SE8702980D0 (sv) 1987-07-28
CY1754A (en) 1994-06-03
JP2632858B2 (ja) 1997-07-23
LU86950A1 (fr) 1988-02-02
NZ221226A (en) 1990-07-26
DE3724059A1 (de) 1988-02-18
KR880001291A (ko) 1988-04-22
HU202108B (en) 1991-02-28
FR2602142A1 (fr) 1988-02-05
HU895334D0 (en) 1990-01-28
IT1218150B (it) 1990-04-12
AU610074B2 (en) 1991-05-16
AU7194691A (en) 1991-05-09
DK392487A (da) 1988-01-31
NO873133L (no) 1988-02-01
ES2010227A6 (es) 1989-11-01
GB9008068D0 (en) 1990-06-06
DK392487D0 (da) 1987-07-28
SE8702980L (sv) 1988-04-28
IL83363A0 (en) 1987-12-31
GB2193633A (en) 1988-02-17
IE61103B1 (en) 1994-10-05
HK4694A (en) 1994-01-28
AU7291091A (en) 1991-05-16
HK2994A (en) 1994-01-21
AU7619087A (en) 1988-02-04
GB9008069D0 (en) 1990-06-06
GB2231265A (en) 1990-11-14
HK2694A (en) 1994-01-21
BE1005921A4 (fr) 1994-03-15
AU637878B2 (en) 1993-06-10
ES2016440A6 (es) 1990-11-01
GB2231264A (en) 1990-11-14

Similar Documents

Publication Publication Date Title
SE504184C2 (sv) Användning av vissa 3-HT3-antagonister för framställning av läkemedel
AU704955B2 (en) Use of CGMP-phosphodiesterase inhibitors to treat impotence
US6512002B2 (en) Methods of treatment for premature ejaculation in a male
DE60008372T2 (de) Pharmazeutisch aktive verbindungen
EP0279114B2 (en) Medicaments for the treatment or prevention of the withdrawal syndrome
GB2208862A (en) Esters and amides of cyclic carboxylic acids and cyclic alcohols and amines
CN101355938A (zh) 取代的酰胺的药学应用
CN103415289A (zh) 前神经原性化合物
JP2003509371A (ja) ５−ヒドロキシトリプタミン・レセプタ／α２アドレナリン作用性レセプタ拮抗薬組成物の投与による運動障害の処置
JPH08183735A (ja) 不安症の治療
EP0282547A1 (en) PROCESS FOR RELIEVING VOMITING CAUSED BY SUBSTANCES USED IN CHEMOTHERAPY AND ANTI-EMETIC AGENTS USED IN SUCH SUBSTANCES.
EP0808166A1 (fr) Medicament destine au traitement des troubles obsessifs compulsifs, de l&#39;apnee du sommeil, des dysfonctions sexuelles, de l&#39;emese et du mal des transports
CA2362918A1 (en) Methods and compositions for treating erectile dysfunction
CN101910126A (zh) 作为大麻素受体之配体的脯氨酸类似物
JPH0532635A (ja) ヒスタミン誘導体の治療への応用と、新規なヒスタミン誘導体と、この誘導体の医薬としての使用
CN107674014B (zh) 含有异吲哚啉片段的3，5-二硝基苯甲酰胺类化合物及其制备方法
WO1996033723A2 (en) Use of benzamide derivatives for treating and/or preventing meniere&#39;s syndrome and motion sickness
AU679305B2 (en) Substituted cyclohexanol esters, their use for treating diseases, and pharmaceutical preparations
US4333945A (en) Thiazoline and imidazoline derivatives useful as minor tranquilizers
IL96797A (en) Manufacture of Pharmaceuticals Containing 1,2,3,9-Tetrahydro-H)] -13-Imidazole-1- (Methyl [
PT85429B (pt) Processo para a preparacao de composicoes farmaceuticas
FR2635977A1 (fr) Utilisation de derives de tetrahydro-4,5,6,7 furopyridines pour obtenir des medicaments destines au traitement de l&#39;obesite
Reid Thionaphthen isosteres of biologically active indole derivatives
MXPA05011808A (en) Uses of ion channel modulating compounds
WO2009054929A1 (en) Cannabinoid-1 receptor modulators useful for the treatment of alzheimer&#39;s disease

Legal Events

Date Code Title Description
NUG Patent has lapsed

Ref document number: 8702980-7

Format of ref document f/p: F